Madrigal Pharmaceuticals, Inc. (MDGL)
| Market Cap | 11.85B |
| Revenue (ttm) | 958.40M |
| Net Income (ttm) | -288.28M |
| Shares Out | 22.94M |
| EPS (ttm) | -12.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 218,433 |
| Open | 523.98 |
| Previous Close | 520.09 |
| Day's Range | 515.08 - 528.28 |
| 52-Week Range | 265.00 - 615.00 |
| Beta | -1.01 |
| Analysts | Strong Buy |
| Price Target | 674.45 (+30.53%) |
| Earnings Date | May 6, 2026 |
About MDGL
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. [Read more]
Financial Performance
In 2025, Madrigal Pharmaceuticals's revenue was $958.40 million, an increase of 432.05% compared to the previous year's $180.13 million. Losses were -$288.28 million, -38.12% less than in 2024.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for MDGL stock is "Strong Buy." The 12-month stock price target is $674.45, which is an increase of 30.53% from the latest price.
News
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Rezdiffra is driving strong revenue growth, with 2025 sales projected near $1 billion and a robust pipeline expansion. Market penetration remains low, offering significant upside, while international growth and new combination therapies are set to accelerate from 2027 onward.
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference ...
Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025
Rezdiffra achieved nearly $1B in first-year net sales, driving robust growth in a rapidly expanding US MASH market. The company expects continued strong performance in 2026, supported by a deep pipeline, broad payer access, and a strong cash position.
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
Fourth -quarter and full-year 2025 Rezdiffra ® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025 , more than 36,250 patients on Rezdiffra Built industry-lea...
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced t...
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thurs...
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Leadership in MASH is reinforced by rapid Rezdiffra adoption, robust market access, and a deepening pipeline with new combination therapies. Financial strategy prioritizes growth and pipeline investment, with profitability expected as revenue outpaces spend. Significant market expansion is anticipated, especially with the F4C indication and ongoing international efforts.
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...
Madrigal Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
Strong sales momentum, robust payer access, and expanding prescriber engagement mark a successful launch phase. Clinical data supports chronic use and de-risks future studies, while strategic business development and patent protection position the company for long-term growth.
Madrigal Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong launch momentum continues with over $1 billion run rate and less than 10% market penetration, supported by robust IP and payer access. Gross-to-net discounts will rise as contracting matures, with international expansion starting in Germany. Pipeline and label expansion remain top priorities.
Madrigal Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Rezdiffra is positioned as a foundational therapy for MASH, with strong long-term growth potential and high persistency rates. Commercial strategy focuses on specialist engagement and patient support, while financial guidance anticipates a gross-to-net impact in the high 30% range for 2026. Clinical trials in advanced populations are progressing, with key results expected in 2027.
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor confer...
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra ...
Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2025
Rezdiffra delivered $287.3M in Q3 2025 net sales, up 35% sequentially, with over 29,500 patients on therapy and more than 10,000 prescribers. Robust U.S. demand, expanding payer access, and a strong pipeline—including a new oral GLP-1—support continued growth into 2026.
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Third -quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025 , more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral...
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra Poster of dis...
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharma CEO talks competition in the liver disease treatment space
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk how Rezdiffra stacks up to competitors in the MASH treatment space, sales growth for the drug over the last year, and more.
Madrigal Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Significant progress was highlighted, including a strong Rezdiffra launch, robust IP protection through 2045, and European expansion. Real-world data supports high efficacy and adherence, while pipeline growth and $500M in financing position the company for long-term leadership in MASH.